|
Viromed Medical AG / Key word(s): Mergers & Acquisitions Viromed Medical AG plans to acquire all shares in pharmedix GmbH by means of a capital increase against a contribution in kind, excluding subscription rights. 03-Dec-2024 / 13:53 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Viromed Medical AG plans to acquire all shares in pharmedix GmbH by means of a capital increase against a contribution in kind, excluding subscription rights. Pinneberg, 3 December 2024 – Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”; the “Company”) plans to acquire all shares in pharmedix GmbH, Hamburg, and thus to expand its portfolio strongly. To this end, the Company signed a corresponding agreement with the shareholders of pharmedix GmbH today. pharmedix GmbH specializes in the development, marketing and distribution of products and brands in the healthcare sector. Through its international network, it has access to the latest technologies and processes in microbiology and pharmaceutics, as well as to the highest quality raw materials and state-of-the-art production facilities. pharmedix’s portfolio includes medical devices and medical cosmetics under the N1® and ORTHOCOMPLEX® brands. The company was founded in 2021. For the 2024 financial year, a nearly balanced operating result is already expected with revenues of more than EUR 4.0 million. For 2025, a revenue growth of 35% to approximately EUR 5.5 million and a positive operating result are planned. The target for the period to 2029 is to achieve average annual revenue growth of 25% and an operating margin of between 15% and 20%. The closing of the acquisition is expected to take effect on 1 January 2025. The transaction is subject to the final results of the due diligence. The purchase price for the complete acquisition of the shares in pharmedix GmbH is expected to be a maximum of EUR 2.0 million. The purchase price payment is to be made exclusively by granting new shares in the company, making partial use of the Authorized Capital 2022, as part of a capital increase against contributions in kind, excluding shareholders’ subscription rights. Contact Viromed Medical AG Uwe Perbandt End of Inside Information 03-Dec-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
RaDonda Vaught Says Some System Practices Contributed to Fatal Mistake
With tears in her eyes, former Vanderbilt nurse RaDonda Vaught, who was criminally convicted of a 2017 drug error that resulted in a patient’s death,
March 15, 2024